Article Sidebar

pdf
Date Published: 10/07/2024
Abstract Views: 48
Views pdf: 5
DOI: https://doi.org/10.51298/vmj.v540i1.10278
Issue
Vol. 540 No. 1 (2024)
Section
Các bài báo
How to Cite
Trần, T. T. H., & Đỗ, T. L. T. (2024). ASSESSMENT OF CHANGES IN PLASMA CYFRA 21-1, CEA, SCC CONCENTRATIONS DURING TREATMENT MONITORING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AT 19-8 HOSPITAL MINISTRY OF PUBLIC SECURITY. Vietnam Medical Journal, 540(1). https://doi.org/10.51298/vmj.v540i1.10278

ASSESSMENT OF CHANGES IN PLASMA CYFRA 21-1, CEA, SCC CONCENTRATIONS DURING TREATMENT MONITORING IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AT 19-8 HOSPITAL MINISTRY OF PUBLIC SECURITY

Thị Thúy Hằng Trần, Thị Lệ Thúy Đỗ

Main Article Content

Abstract

Objective: Determine plasma Cyfra 21-1, CEA, SCC concentrations, and changes in Cyfra 21-1, CEA, SCC concentrations during treatment in patients with non-small cell lung cancer at 19-8 Hospital Ministry of Public Security. Methods: Prospective descriptive study on 41 patients diagnosed with non-small cell lung cancer at 19-8 Hospitals from April 2023 to February 2024. All patients were tested to quantify CEA, SCC, and Cyfra 21-1 levels before and 1 month after treatment. Results: CEA, Cyfra 21-1, SCC concentrations in the group of patients with newly discovered disease before and after treatment were 36.65 and 28.96 ng/mL; 1.57 and 1.48 ng/mL; 6.78 and 4.39 ng/mL; respectively. The group of relapsed patients also showed similar results with a significant decrease in the concentrations of 3 markers CEA, SCC, and Cyfra 21-1 to 279.22 and 271.44 ng/mL; 2.94 and 1.61 ng/mL; 8.61 and 5.67 ng/mL, respectively; a significant difference with p < 0.05. Conclusion: The change in concentrations of 3 markers tends to gradually decrease in both groups of subjects during treatment.

Article Details

Keywords

Non-small cell lung cancer (NSCLC), Cyfra 21-1, CEA, SCC.

References

Global Cancer Observatory. Published (2022) https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf
2. Nguyễn Bá Đức (2010). Điều trị nội khoa bệnh ung thư, 81 – 99. Hà Nội, Nhà xuất bản y học,.
3. Feng Chen, Xiu-Ying Wang, et al (2015). Diagnostic value of Cyfra21-1, SCC and CEA for differentiation of early-stage NSCLC from benign lung disease. Int J Clin Exp Med, 8(7), 11295 – 11300.
4. Hàn Thị Thanh Bình (2018). Nghiên cứu điều trị ung thư phổi không tế bào nhỏ giai đoạn IIIB, IV bằng hóa trị phác đồ cisplatin kết hợp với paclitaxel hoặc etoposide. Luận án Tiến sỹ Y học, Trường Đại học Y Hà Nội.
5. Vũ Lan Anh, Trần Huy Thịnh (2019). Khảo sát nồng độ CEA, SCC, Cyfra 21-1 huyết tương trong theo dõi điều trị bệnh nhân ung thư phổi không tế bào nhỏ, Tạp chí Nghiên cứu Y học, 123 (7), 26-32
6. Benjamin M Robinson, Catherine Kennedy, Jocelyn McLean et al (2011). Node-negative Non-small cell lung cancer: Pathological staging and survival in 1765 consecutive cases. J Thorac Oncol, 6(10), 1691 – 1696.
7. Lại Thị Tố Uyên (2015). Khảo sát nồng độ bộ 3 marker CYFRA 21-1, CEA, SCCA ở bệnh nhân ung thư phổi không tế bào nhỏ tại trung tâm ung bướu và y học hạt nhân, Bệnh viện Bạch Mai năm 2014. Tạp chí y học thực hành, 4(958), 62 – 65.
8. Dal Bello M. G., Filiberti R. A., (2019). The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients, Journal of Translational Medicine, 17(1): 74 doi: 10.1186/ s12967-019-1828-0.
9. Akihiro Yoshimura 1, Junji Uchino, (2019). Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer, Transl Lung Cancer Res, 8(3):227-234, doi: 10.21037/tlcr.2019.06.08.
10. Masaki Tomita, Shoei Kuroki (2021). Impact of Preoperative Serum Tumor Markers in Patients with Lung Squamous Cell Carcinoma, Scientific Research Publishing, 10(03):48-55.